Fish oils in chronic kidney disease

A 12 week intervention examining the effect of fish oil on appetite, inflammatory markers and nutritional parameters in dialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12607000455460

Enrollment

Registered

2007-09-10

Start date

2007-06-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to explore the effect of EPA (fish oil) on appetite, inflammatory markers and nutritional parameters in dialysis patients. Previous research has shown anti-inflammatory effects from fish oil and there is some evidence to indicate that poor appetite may be associated with inflammation. We aim to explore this relationship.

Interventions

All participants are given a fish oil supplement containing 2g Eicosapentaenoic Acid (EPA) per day for 12 weeks (capsules or oil, participants choice). All outcomes (appetite, inflammatory, nutritional, quality of life) are measured at baseline and 12 weeks. Appetite also measured at wk 4 and wk 12. Participants consent to pre-baseline data being used as historical control.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Adult chronic kidney disease patients aged > 18 years who have been receiving hemodialysis for > 3 months.

Exclusion criteria

Taking a fish oil supplement providing > 500 mg/day, aged < 18 years, on hemodialysis < 3 months, presence of emotional, cognitive or language limitations impairing their ability to provide informed consent or follow study instructions (where a carer or translator is not available).

Outcome results